ACBI3 molecule offers new hope for targeting KRAS mutations in cancer

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.